Phase 1 Trial of Vaccination With Autologous Tumor Cells and Antisense Directed Against the Insulin Growth Factor Type 1 Receptor (IGF-1R AS ODN) in Patients With Recurrent Glioblastoma
JHN Journal
doi 10.29046/jhnj.013.1.002
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2018
Authors
Publisher
Thomas Jefferson University